Soligenix Inc SNGX

NAS: SNGX | ISIN: US8342233074   30/04/2025
1,970 USD (-0,51%)
(-0,51%)   30/04/2025

14 april 2025 · Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks · Persbericht

25 maart 2025 · Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants · Persbericht

21 maart 2025 · Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results · Persbericht

6 maart 2025 · HyBryte™ Treatment Studies Presented at Two Medical Conferences in March · Persbericht

3 september 2024 · Soligenix Receives European Patent for Improved Production of Synthetic Hypericin · Persbericht

9 augustus 2024 · Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results · Persbericht

9 juli 2024 · Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma · Persbericht

25 juni 2024 · Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma · Persbericht

14 juni 2024 · A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference · Persbericht

31 mei 2024 · Soligenix Announces Reverse Stock Split · Persbericht

29 mei 2024 · Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting · Persbericht

24 mei 2024 · Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting · Persbericht

23 mei 2024 · Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split · Persbericht

21 mei 2024 · SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference · Persbericht

20 mei 2024 · Soligenix Encourages Stockholders to Vote Prior to Annual Meeting · Persbericht

16 mei 2024 · Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice · Persbericht

10 mei 2024 · Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results · Persbericht

6 mei 2024 · Soligenix to Present at Upcoming Conferences · Persbericht

25 april 2024 · Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa · Persbericht

18 april 2024 · Soligenix Announces Pricing of $4.75 Million Public Offering · Persbericht

Mijn selecties